Pilz Bioscience

Pilz Bioscience was a private biotechnology company focused on developing medicinal psychedelics for neuroinflammatory conditions with significant cognitive components and high unmet need. Its initial therapeutic focus was autism spectrum disorder, where it aimed to combine a proprietary diagnostic and treatment framework with psilocybin-derived therapeutics. Public descriptions of the company emphasize a systems-level approach linking inflammation, the oral/gut/brain axis, and behavior. Pilz was acquired by Nova Mentis Life Science on November 30, 2020, and appears to have ceased operating as an independent company thereafter. The company was therefore an early-stage, preclinical psychedelic-biotech asset rather than a commercial operating business.